Skip to main content
    R

    Rxsight Inc (RXST)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $5.30
    -0.02 (-0.38%)

    Market Cap: $223.06M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Rxsight Inc (RXST) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Rxsight (RXST) to earn -$0.13 per share in the fiscal year ending Dec 31, 2026, on revenue of $146.75M. Of 10 analysts, 1 rates the stock Buy or Strong Buy, 7 Hold and 2 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 3.20, inside the Hold band from 2.5 up to 3.5. Sell and Strong Sell make up 20% of the ratings.

    RatingAnalystsShare
    Strong Buy110.0%
    Buy00.0%
    Hold770.0%
    Sell00.0%
    Strong Sell220.0%
    Consensus
    Hold
    Total analysts
    10

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates fall 21.1%.

    Fiscal year ending Dec 31, 2026
    -$0.13
    EPS consensus, revenue $146.75M
    Fiscal year ending Dec 31, 2027
    -$0.67
    EPS consensus, revenue $115.72M

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.13-$0.14 to -$0.103$146.75M$143.07M to $149.00M10
    Dec 31, 2027-$0.67-$1.06 to -$0.415$115.72M$106.02M to $123.00M10

    Quarterly Estimates

    The EPS consensus falls from $0.11 for the quarter ending Dec 31, 2026 to -$0.14 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$0.11-$0.31 to $0.2612$58.68M$52.77M to $62.79M12
    Mar 31, 2027-$0.14-$0.14 to -$0.132$29.64M$26.32M to $32.60M3

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202601
    Fiscal year ending Dec 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.27.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$0.13-$0.13-$0.28-$0.27-$0.27N/A
    Fiscal year ending Dec 31, 2027-$0.67-$0.73-$0.68-$0.70-$0.70N/A
    Quarter ending Mar 31, 2027-$0.14-$0.11-$0.19-$0.19-$0.17N/A

    Frequently Asked Questions About RXST

    What is the RXST stock forecast?

    Consensus analyst estimates put Rxsight's EPS at -$0.13 for the fiscal year ending Dec 31, 2026, on revenue of $146.75M. The consensus rating from 10 analysts is Hold.

    How do analysts rate RXST stock?

    Of 10 analysts covering Rxsight, 1 rates it Strong Buy, 0 Buy, 7 Hold, 0 Sell and 2 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from RXST next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.13, with estimates from -$0.14 to -$0.10 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.67, with estimates from -$1.06 to -$0.41 from 5 analysts.

    What revenue do analysts expect from Rxsight next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $146.75M, with estimates from $143.07M to $149.00M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $115.72M, with estimates from $106.02M to $123.00M.

    How many analysts cover RXST?

    10 analysts rate Rxsight stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.